Literature DB >> 31354091

Yap overexpression attenuates septic cardiomyopathy by inhibiting DRP1-related mitochondrial fission and activating the ERK signaling pathway.

Wancheng Yu1, Xu Mei2, Qian Zhang1, Haizhou Zhang1, Tao Zhang1, Chengwei Zou1.   

Abstract

Context: Yes-associated protein (Yap) has been linked to several cardiovascular disorders, but the role of this protein in septic cardiomyocytes is not fully understood. Objective: The aim of our study was to explore the influence of Yap in septic cardiomyopathy in vivo and in vitro. Materials and methods: In the current study, Yap transgenic mice and Yap adenovirus-mediated gain-of-function assays were used in an LPS-established septic cardiomyopathy model. Mitochondrial function and mitochondrial fission were determined through western blotting, immunofluorescence analysis and ELISA.
Results: Our results demonstrated that Yap expression was downregulated by LPS, whereas Yap overexpression sustained cardiac function and attenuated cardiomyocyte death. The functional exploration revealed that LPS treatment induced cardiomyocyte mitochondrial stress, as manifested by mitochondrial superoxide overproduction, cardiomyocyte ATP deprivation, and caspase-9 apoptosis activation. Furthermore, we demonstrated that LPS-mediated mitochondrial damage was controlled by mitochondrial fission. However, Yap overexpression reduced mitochondrial fission and therefore improved mitochondrial function. A molecular investigation revealed that Yap overexpression inhibited mitochondrial fission by reversing ERK activity, and the inhibition of the ERK pathway promoted DRP1 upregulation and thereby mediated mitochondrial fission activation in the presence of Yap overexpression. Conclusions: Overall, our results suggest that the cause of septic cardiomyopathy appears to be connected with Yap downregulation. The overexpression of Yap can attenuate myocardial inflammation injury through the reduction of DRP1-related mitochondrial fission in an ERK pathway activation-dependent manner.

Entities:  

Keywords:  Drp1; ERK; Yap; cardiomyocytes; mitochondrial fission; septic cardiomyopathy

Mesh:

Substances:

Year:  2019        PMID: 31354091     DOI: 10.1080/10799893.2019.1641822

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  6 in total

Review 1.  Therapeutic Strategies Targeting Mitochondrial Dysfunction in Sepsis-induced Cardiomyopathy.

Authors:  Oluwabukunmi Modupe Salami; Olive Habimana; Jin-Fu Peng; Guang-Hui Yi
Journal:  Cardiovasc Drugs Ther       Date:  2022-06-15       Impact factor: 3.727

2.  The YAP/SERCA2a signaling pathway protects cardiomyocytes against reperfusion-induced apoptosis.

Authors:  Jiankai Zhong; Haichun Ouyang; Sulin Zheng; Zhongzhou Guo; Yuying Chen; Yuanlin Zhong; Wenhao Zhong; Liuer Zuo; Jianhua Lu
Journal:  Aging (Albany NY)       Date:  2020-07-09       Impact factor: 5.682

3.  SirT3 activates AMPK-related mitochondrial biogenesis and ameliorates sepsis-induced myocardial injury.

Authors:  Ting Xin; Chengzhi Lu
Journal:  Aging (Albany NY)       Date:  2020-07-28       Impact factor: 5.682

4.  Receptor-Interacting Protein Kinase 3 Suppresses Mitophagy Activation via the Yes-Associated Protein/Transcription Factor EB Pathways in Septic Cardiomyopathy.

Authors:  Pingjun Zhu; Yangxiaocao Chen; Junyan Wang; Geng Lin; Runsheng Wang; Yifan Que; Jin Zhou; Guogang Xu; Jiang Luo; Yingzhen Du
Journal:  Front Cardiovasc Med       Date:  2022-03-24

5.  Apelin-13 Pretreatment Promotes the Cardioprotective Effect of Mesenchymal Stem Cells against Myocardial Infarction by Improving Their Survival.

Authors:  Guona Chen; Xiaoting Liang; Qian Han; Cong Mai; Linli Shi; Zhuang Shao; Yimei Hong; Fang Lin; Mimi Li; Bei Hu; Xin Li; Yuelin Zhang
Journal:  Stem Cells Int       Date:  2022-03-21       Impact factor: 5.443

Review 6.  Current Status of Septic Cardiomyopathy: Basic Science and Clinical Progress.

Authors:  Huan Lin; Wenting Wang; Madeline Lee; Qinghe Meng; Hongsheng Ren
Journal:  Front Pharmacol       Date:  2020-03-03       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.